Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International Delphi-based Consensus: Therapeutic Approaches for Pediatric Adrenocortical Carcinoma.

European journal of endocrinology·2026
Same author

Gender disparities in historical context, workforce structure, and decision-making.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same author

Upfront management of brain metastases in oncogene‑addicted NSCLC - An EORTC survey.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Exploring Thoracic Radiotherapy in Metastatic NSCLC: A Retrospective Review in the Era of Immunotherapy and Targeted Therapies.

Clinical lung cancer·2026
Same author

<i>THRB</i> splice site variants lead to exon 4 skipping and TRβ1 gain-of-function syndrome.

medRxiv : the preprint server for health sciences·2026
Same author

Anaplastic thyroid cancer: Cases, incidence, prevalence and survival in Germany.

Endocrine·2026
Same journal

Continuous glucose monitoring-derived time in range is associated with changes in arterial stiffness in type 2 diabetes.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Association of the Primary Aldosteronism Severity Classification with Lateralization and Treatment Outcomes.

The Journal of clinical endocrinology and metabolism·2026
Same journal

From Premature Adrenarche to Adult Metabolic Risk and Hyperandrogenism: A Systematic Review and Meta-Analysis.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Open-Label 9-Year Follow-Up Extension Phase 2 Study of Once-Weekly Somatrogon in Children With Growth Hormone Deficiency.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Correction to: "CAHQL: A Patient-Reported Outcome Instrument to Assess Health-Related Quality of Life in Congenital Adrenal Hyperplasia".

The Journal of clinical endocrinology and metabolism·2026
Same journal

Approach to Personalizing the Treatment of Osteoporosis.

The Journal of clinical endocrinology and metabolism·2026
See all related articles

Related Experiment Video

Updated: Apr 29, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.1K

Outcome Of First-Line Chemotherapy For Anaplastic Thyroid Cancer - A Multicenter Registry Analysis.

Katharina Elisabeth Graf1, Pia Adam1, Felix Megerle2

  • 1Department of Internal Medicine IV, University Hospital Munich, LMU Munich, Munich, Germany.

The Journal of Clinical Endocrinology and Metabolism
|April 28, 2026
PubMed
Summary
This summary is machine-generated.

Carboplatin-paclitaxel (CP) chemotherapy did not improve survival outcomes for anaplastic thyroid cancer (ATC) patients compared to other regimens. Treatment success in ATC depends on disease burden and resectability, highlighting the need for molecular diagnostics.

Keywords:
carboplatincytotoxic chemotherapydoxorubicinoverall survivalpaclitaxelprogression-free survival

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

24.0K

Related Experiment Videos

Last Updated: Apr 29, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.1K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

24.0K

Area of Science:

  • Oncology
  • Thyroid Cancer Research

Background:

  • Anaplastic thyroid cancer (ATC) has a poor prognosis, with limited treatment options.
  • Current guidelines recommend multimodal therapy, but optimal chemotherapy regimens are not established.
  • Carboplatin-paclitaxel (CP) is a common first-line treatment in Germany for ATC.

Purpose of the Study:

  • To compare the efficacy of first-line carboplatin-paclitaxel (CP) chemotherapy with or without radiotherapy against other cytotoxic chemotherapy regimens in ATC patients.
  • To identify prognostic factors influencing survival in ATC.

Main Methods:

  • Retrospective multicenter registry study conducted in Germany.
  • 158 adult patients with histologically confirmed ATC treated with first-line cytotoxic chemotherapy were analyzed.
  • Progression-free survival (PFS) and overall survival (OS) were compared using Kaplan-Meier and log-rank tests; Cox proportional hazard models identified risk factors.

Main Results:

  • No significant difference in PFS or OS was observed between CP and other chemotherapy regimens.
  • Complete response rates were similar between the CP group (13%) and the other chemotherapy group (8%).
  • Advanced age, lymph node metastasis, and distant metastasis were associated with increased mortality, while surgery was linked to lower mortality.

Conclusions:

  • First-line CP chemotherapy did not demonstrate a survival benefit in anaplastic thyroid cancer.
  • Patient outcomes are primarily influenced by disease burden and resectability, emphasizing the importance of rapid molecular diagnostics.
  • Chemotherapy can serve as a temporary measure while awaiting definitive treatment strategies.